Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2019

View Archived Issues

Inducing HER2 expression to sensitize tumors

Size matters for cell prowess

T cells ChAT with blood vessels via neurotransmitter

Debiopharm initiates phase II FUZE study of Debio-1347

Vertex presents positive phase III study data for tezacaftor/ivacaftor

Advaxis initiates phase I/II study of ADXS-503 in patients with NSCLC

Phase III studies of brexpiprazole in patients with bipolar I disorder do not meet primary endpoint

KA-11 demonstrates promising activity in preclinical models of epilepsy and pain

MELK as a novel therapeutic target for neuroblastoma

University of Utah, Stingray Therapeutics patent E-NPP 1 inhibitors/STING modulators

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

New PAI-1 inhibitors presented by Eastern Michigan University and the University of Michigan

IL-13Ralpha2 as a novel marker and potential therapeutic target for malignant melanoma

The Helleday Foundation describes ADP-sugar pyrophosphatase inhibitors

New selective estrogen receptor degradation inducers patented by Zeno Royalties & Milestones

Loss of miR-7 facilitates gastric cancer metastasis: a potential biomarker and therapeutic target

TRIM14 promotes tumor invasion in glioblastoma, and may be a novel therapeutic target

AbCellera Biologics and Novartis enter multitarget collaboration

Forbius enters collaboration to evaluate TGF-beta inhibitor in myelofibrosis

Kymab begins phase I/II study of KY-1044 and atezolizumab in advanced cancers

PellePharm initiates phase III study of patidegib topical gel in basal cell nevus syndrome

Transgenic mouse model allows differentiation of platelet and leukocyte functions

ApoE-complement link opens door for new targets in Alzheimer's, atherosclerosis

New 64-week data reported from phase III study of Crysvita in X-linked hypophosphatemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...